Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...
Scan-Rescan Sub-Study of MS PATHS
- Conditions
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT04123353
- Locations
- 🇺🇸
Research Site, Cleveland, Ohio, United States
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
- Conditions
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Biogen
- Registration Number
- NCT04106050
Angelman Syndrome (AS) Biomarker Study
- Conditions
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT04103333
- Locations
- 🇺🇸
Rush Medical College, Chicago, Illinois, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸University of North Carolina Hospital, Carolina, North Carolina, United States
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 145
- Registration Number
- NCT04089566
- Locations
- 🇯🇵
Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo-To, Japan
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇷🇺Regional Pediatric Clinical Hospital #1, Ekaterinburg, Russian Federation
A Real-world Study of Imraldi® Use
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1000
- Registration Number
- NCT04089514
- Locations
- 🇬🇧
Research Site, Sussex, United Kingdom
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 31
- Registration Number
- NCT04079101
- Locations
- 🇺🇸
Research Site, Long Beach, California, United States
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Biogen
- Registration Number
- NCT04079088
A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT04068532
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT04056689
- Locations
- 🇳🇱
QPS, Leeuwarden, Netherlands
🇬🇧Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, United Kingdom
🇧🇪UZ Leuven, Leuven, Belgium
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 53
- Registration Number
- NCT04007367
- Locations
- 🇺🇸
Sage Investigational Site, Everett, Washington, United States